Education
About Us
Working with TipRanks
Follow Us
IQVIA Holdings (GB:0JDM)
:0JDM
0JDM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$138.86 - $252.90
Previous CloseN/A
Volume694.00
Average Volume (3M)193.00
Market Cap
$26.50B
Enterprise Value$48.17B
Total Cash (Recent Filing)$1.70B
Total Debt (Recent Filing)$1.32B
Price to Earnings (P/E)19.9
Beta1.05
Next Earnings
May 06, 2025EPS Estimate
2.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.50
Shares Outstanding176,315,030
10 Day Avg. Volume157
30 Day Avg. Volume193
Financial Highlights & Ratios
PEG Ratio8.07
Price to Book (P/B)N/A
Price to Sales (P/S)2.12
Price to Cash Flow (P/CF)9.30
P/FCF Ratio8.00
Enterprise Value/Market Cap1.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.96
Enterprise Value/Ebitda14.17
Forecast
1Y Price Target
$212.75Price Target Upside41.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
AI IntegrationIQV's initiatives to incorporate AI to enhance all aspects of its operations and products have shown positive results, winning contracts with customers.
Earnings DiversificationIQV's earnings diversification, with 45% of earnings coming from TAS, a segment seeing a rebound in demand and driving margin recovery.
Market ExposureIQV's broader exposure to the market is expected to allow it to be less impacted by overall macro pressures compared to peers.
Bears Say
Cancellation RatesStill-elevated cancellation rates are further evidence that the expected recovery in clinical trial demand is not going to be linear.
R&D Growth ChallengesRDS business will likely be impacted by challenging conditions, including slower R&D growth among top 20 pharma and subdued biotech activity.
Tariff ImpactsPotential tariffs on pharma imports could lead IQV clients to pull back on discretionary spending, impacting a significant portion of the company's revenue.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.85% Insiders
23.80%
Mutual Funds
25.61% Other Institutional Investors
25.26% Public Companies and
Individual Investors
0JDM FAQ
What was IQVIA Holdings’s price range in the past 12 months?
IQVIA Holdings lowest share price was $138.86 and its highest was $252.90 in the past 12 months.
What is IQVIA Holdings’s market cap?
IQVIA Holdings’s market cap is $26.50B.
When is IQVIA Holdings’s upcoming earnings report date?
IQVIA Holdings’s upcoming earnings report date is May 06, 2025 which is in 10 days.
How were IQVIA Holdings’s earnings last quarter?
IQVIA Holdings released its earnings results on Feb 06, 2025. The company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $3.109 by $0.011.
Is IQVIA Holdings overvalued?
According to Wall Street analysts IQVIA Holdings’s price is currently Undervalued.
Does IQVIA Holdings pay dividends?
IQVIA Holdings does not currently pay dividends.
What is IQVIA Holdings’s EPS estimate?
IQVIA Holdings’s EPS estimate is 2.63.
How many shares outstanding does IQVIA Holdings have?
IQVIA Holdings has 176,315,030 shares outstanding.
What happened to IQVIA Holdings’s price movement after its last earnings report?
IQVIA Holdings reported an EPS of $3.12 in its last earnings report, beating expectations of $3.109. Following the earnings report the stock price went up 2.391%.
Which hedge fund is a major shareholder of IQVIA Holdings?
Currently, no hedge funds are holding shares in GB:0JDM
---
IQVIA Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$212.75 (41.86% Upside)
$212.75 (41.86% Upside)
Blogger Sentiment
Bullish
GB:0JDM Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $255.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.77%
12-Months-Change
Fundamentals
Return on Equity
22.55%
Trailing 12-Months
Asset Growth
0.82%
Trailing 12-Months
Company Description
IQVIA Holdings
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
---
0JDM Company Deck
---
0JDM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
IQVIA delivered strong results in 2024, with notable achievements in revenue and strategic partnerships, alongside advancements in AI and global health initiatives. However, the significant cancellations and challenging macroeconomic conditions posed considerable hurdles. The outlook remains cautiously optimistic with expected volatility in some segments.Read More>---
0JDM Revenue Breakdown
55.35% Research & Development Solutions
39.99% Technology & Analytics Solutions
4.66% Contract Sales & Medical Solutions
---
0JDM Stock 12 Month Forecast
Average Price Target
$212.75
▲(41.86% Upside)
Technical Analysis
Best Analysts Covering 0JDM
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+10.19%
upgraded a buy rating 5 months ago
Copying Jack Meehan's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +10.19% per trade.
---